Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study
Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study
Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib
Read more at prnewswire.com